Johnson & Johnson (NYSE:JNJ) Shares Sold by Pekin Hardy Strauss Inc.

Pekin Hardy Strauss Inc. trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJFree Report) by 2.3% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 29,671 shares of the company’s stock after selling 692 shares during the period. Pekin Hardy Strauss Inc.’s holdings in Johnson & Johnson were worth $4,621,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of JNJ. Moneta Group Investment Advisors LLC increased its holdings in shares of Johnson & Johnson by 90,144.4% during the fourth quarter. Moneta Group Investment Advisors LLC now owns 54,386,720 shares of the company’s stock valued at $9,607,414,000 after purchasing an additional 54,326,454 shares during the period. Norges Bank acquired a new position in Johnson & Johnson during the fourth quarter worth about $4,609,399,000. Capital International Investors lifted its holdings in Johnson & Johnson by 62.7% in the 2nd quarter. Capital International Investors now owns 27,825,795 shares of the company’s stock valued at $4,605,627,000 after acquiring an additional 10,724,110 shares during the last quarter. Journey Strategic Wealth LLC boosted its position in shares of Johnson & Johnson by 161,420.2% during the 2nd quarter. Journey Strategic Wealth LLC now owns 7,276,483 shares of the company’s stock valued at $1,204,404,000 after purchasing an additional 7,271,978 shares in the last quarter. Finally, Morgan Stanley grew its stake in shares of Johnson & Johnson by 12.0% in the 4th quarter. Morgan Stanley now owns 42,224,521 shares of the company’s stock worth $7,458,962,000 after purchasing an additional 4,521,062 shares during the last quarter. 68.40% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $156.76 on Friday. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.21 and a quick ratio of 0.96. Johnson & Johnson has a fifty-two week low of $144.95 and a fifty-two week high of $175.97. The stock’s 50-day moving average is $158.20 and its two-hundred day moving average is $158.83. The firm has a market cap of $377.37 billion, a P/E ratio of 11.35, a PEG ratio of 2.63 and a beta of 0.53.

Johnson & Johnson (NYSE:JNJGet Free Report) last issued its earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share for the quarter, topping the consensus estimate of $2.28 by $0.01. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. The company had revenue of $21.40 billion for the quarter, compared to analyst estimates of $21.02 billion. During the same period in the prior year, the firm posted $2.35 EPS. The business’s revenue was down 9.7% compared to the same quarter last year. Analysts predict that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, March 5th. Shareholders of record on Tuesday, February 20th will be given a $1.19 dividend. This represents a $4.76 annualized dividend and a yield of 3.04%. The ex-dividend date is Friday, February 16th. Johnson & Johnson’s payout ratio is currently 34.47%.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on JNJ shares. Morgan Stanley reduced their target price on shares of Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating for the company in a report on Wednesday, January 24th. Raymond James boosted their target price on Johnson & Johnson from $172.00 to $175.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 3rd. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a report on Tuesday, February 6th. Wells Fargo & Company downgraded Johnson & Johnson from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $170.00 to $163.00 in a report on Wednesday, December 13th. Finally, TheStreet downgraded Johnson & Johnson from a “b” rating to a “c+” rating in a report on Friday, November 17th. Eight equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $176.14.

Get Our Latest Stock Analysis on Johnson & Johnson

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Featured Stories

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.